EMA Authorised: Bysumlog (insulin lispro) — Gan & Lee Pharmaceuticals Europe GmbH

View source ↗

Summary

EMA authorised Bysumlog (insulin lispro) by Gan & Lee Pharmaceuticals Europe GmbH for diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Bysumlog (insulin lispro)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Gan & Lee Pharmaceuticals Europe GmbH. Decision date: 22/08/2026